Burdelski M, Rodeck B, Latta A, Latta K, Brodehl J, Ringe B, Pichlmayr R
Kinderklinik Medizinische Hochschule Hannover, Germany.
J Inherit Metab Dis. 1991;14(4):604-18. doi: 10.1007/BF01797930.
Among the worldwide accepted indications for liver transplantation, inherited metabolic disorders play an increasing role. In some paediatric centres this indication runs second after extrahepatic biliary atresia. The aim of liver transplantation in inherited metabolic disorders is twofold: the first is to save a patient's life, the second is to accomplish phenotypic and functional cure of his disease. These aims may be achieved in disorders presenting with cirrhosis, hepatoma, life-threatening progression or failure of other organs with preserved liver function. The timing of liver transplantation has become easier with development of surgical techniques of reduced-size donor livers. These techniques enable the performance of liver transplantation with ABO blood group compatible organs of almost any size if indicated either by deterioration of liver function or impending complications such as hepatoma or life-threatening progression. In comparison with other indications such as extrahepatic biliary atresia, postnecrotic liver cirrhosis or acute liver failure, the results of transplantation in patients with inherited metabolic disorders seem to be better, reaching up to 78-95% actuarial 1-year survival rates. However, lifelong immunosuppressive therapy is necessary. This seems to be acceptable even in disorders with only partial liver function defects.
在全球公认的肝移植适应证中,遗传性代谢紊乱的作用日益凸显。在一些儿科中心,这一适应证仅次于肝外胆道闭锁,位居第二。遗传性代谢紊乱患者进行肝移植的目的有两个:一是挽救患者生命,二是实现疾病的表型和功能治愈。对于出现肝硬化、肝癌、危及生命的进展或其他器官功能衰竭但肝功能尚保存的疾病,这些目标或许能够达成。随着减体积供肝手术技术的发展,肝移植的时机选择变得更为容易。如果出现肝功能恶化或诸如肝癌或危及生命的进展等即将发生的并发症,这些技术能够使用几乎任何大小的 ABO 血型相容器官进行肝移植。与肝外胆道闭锁、坏死后肝硬化或急性肝衰竭等其他适应证相比,遗传性代谢紊乱患者的移植结果似乎更好,1 年实际生存率高达 78% - 95%。然而,终身免疫抑制治疗是必要的。即便在仅有部分肝功能缺陷的疾病中,这似乎也是可以接受的。